InsiderTrades.com logo
Let’s be blunt
From DTI   |   Ad
Let me be blunt with you for just a second… You may think you know when and why stocks move, but you’re wrong… Most traders have no idea about the biggest secret Wall Street keeps — even though it’s hiding in plain sight. But once you’ve cracked this code… It could be the breakthrough you need to start targeting $100-$150 a day in the stock market (starting with just $1,000)!
Check out the $100 Challenge now
Elizabeth Crowley net worth and biography
  • LinkedIn
  • Phone
  • Email
  • Website

Elizabeth Crowley Biography and Net Worth

VP of Celldex Therapeutics
Elizabeth Crowley is Senior Vice President, Chief Product Development Officer of Celldex. Ms. Crowley joined Celldex in 2009 as Vice President, Clinical Development. Prior to that, she held several senior level roles at CuraGen Corporation, most recently serving as the Vice President of Development Operations, responsible for strategic and operational development activities of the oncology and oncology supportive care portfolio, regulatory affairs, clinical operations and data management. Ms. Crowley started her career at Bayer Corporation in 1992, holding various positions providing leadership of clinical research and project management prior to completing her tenure there as the Director of Global Study Audit Management, assuring the highest standards for program execution. Ms. Crowley received her BS in Chemistry with a concentration in Business from Boston College.

What is Elizabeth Crowley's net worth?

The estimated net worth of Elizabeth Crowley is at least $213,692.70 as of June 14th, 2024. Ms. Crowley owns 9,074 shares of Celldex Therapeutics stock worth more than $213,693 as of November 17th. This net worth estimate does not reflect any other investments that Ms. Crowley may own. Additionally, Ms. Crowley receives an annual salary of $507,240.00 as VP at Celldex Therapeutics. Learn More about Elizabeth Crowley's net worth.

How old is Elizabeth Crowley?

Ms. Crowley is currently 52 years old. There are 9 older executives and no younger executives at Celldex Therapeutics. The oldest executive at Celldex Therapeutics is Prof. Joseph P. Schlessinger Ph.D., Co-Founder & Member of Scientific Advisory Board, who is 79 years old. Learn More on Elizabeth Crowley's age.

What is Elizabeth Crowley's salary?

As the VP of Celldex Therapeutics, Inc., Ms. Crowley earns $507,240.00 per year. There are 6 executives that earn more than Ms. Crowley. The highest earning executive at Celldex Therapeutics is Mr. Anthony S. Marucci M.B.A., Founder, President, CEO & Director, who commands a salary of $1,270,000.00 per year. Learn More on Elizabeth Crowley's salary.

How do I contact Elizabeth Crowley?

The corporate mailing address for Ms. Crowley and other Celldex Therapeutics executives is 53 FRONTAGE ROAD SUITE 220, HAMPTON NJ, 08827. Celldex Therapeutics can also be reached via phone at (908) 454-7120 and via email at [email protected]. Learn More on Elizabeth Crowley's contact information.

Has Elizabeth Crowley been buying or selling shares of Celldex Therapeutics?

Elizabeth Crowley has not been actively trading shares of Celldex Therapeutics over the course of the past ninety days. Most recently, Elizabeth Crowley sold 30,000 shares of the business's stock in a transaction on Friday, June 14th. The shares were sold at an average price of $34.87, for a transaction totalling $1,046,100.00. Following the completion of the sale, the vice president now directly owns 9,074 shares of the company's stock, valued at $316,410.38. Learn More on Elizabeth Crowley's trading history.

Who are Celldex Therapeutics' active insiders?

Celldex Therapeutics' insider roster includes Sarah Cavanaugh (SVP), Elizabeth Crowley (VP), Freddy Jimenez (SVP), Samuel Martin (CFO), Anthonly Marucci (President & CEO), and Diane Young (SVP). Learn More on Celldex Therapeutics' active insiders.

Are insiders buying or selling shares of Celldex Therapeutics?

In the last year, Celldex Therapeutics insiders bought shares 1 times. They purchased a total of 11,500 shares worth more than $308,430.00. In the last year, insiders at the biopharmaceutical company sold shares 8 times. They sold a total of 266,332 shares worth more than $9,155,821.33. The most recent insider tranaction occured on November, 11th when CEO Anthony S Marucci bought 11,500 shares worth more than $308,430.00. Insiders at Celldex Therapeutics own 3.8% of the company. Learn More about insider trades at Celldex Therapeutics.

Information on this page was last updated on 11/11/2024.

Elizabeth Crowley Insider Trading History at Celldex Therapeutics

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
6/14/2024Sell30,000$34.87$1,046,100.009,074View SEC Filing Icon  
6/7/2024Sell15,000$35.06$525,900.009,074View SEC Filing Icon  
5/30/2024Sell38,597$33.64$1,298,403.089,074View SEC Filing Icon  
12/8/2021Sell4,000$40.00$160,000.00View SEC Filing Icon  
See Full Table

Elizabeth Crowley Buying and Selling Activity at Celldex Therapeutics

This chart shows Elizabeth Crowley's buying and selling at Celldex Therapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Celldex Therapeutics Company Overview

Celldex Therapeutics logo
Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases. The company's clinical development programs CDX-0159, a Phase II monoclonal antibody that binds the receptor tyrosine kinase KIT and inhibits its activity. It has research collaboration and license agreements with Yale University. The company was incorporated in 1983 and is headquartered in Hampton, New Jersey.
Read More

Today's Range

Now: $23.55
Low: $23.49
High: $25.89

50 Day Range

MA: $31.89
Low: $23.55
High: $44.16

2 Week Range

Now: $23.55
Low: $23.49
High: $53.18

Volume

1,249,780 shs

Average Volume

1,057,140 shs

Market Capitalization

$1.56 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.6
Let’s be blunt
From DTI   |   Ad
Let me be blunt with you for just a second… You may think you know when and why stocks move, but you’re wrong… Most traders have no idea about the biggest secret Wall Street keeps — even though it’s hiding in plain sight. But once you’ve cracked this code… It could be the breakthrough you need to start targeting $100-$150 a day in the stock market (starting with just $1,000)!
Check out the $100 Challenge now